Why United Therapeutics Corporation (UTHR) stock moved
Updated Sep 30, 2026
United Therapeutics Corporation (UTHR) shares climbed 12.6% to $542.22 as of September 30, 2026, a sharp gain from the prior close of $481.47. BestStocks flagged the session as a major change for UTHR. Below, we break down what changed for UTHR, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
UTHR climbed 12.6% to $542.22
United Therapeutics surged +14.51% to $551.32 after a federal court ruled unfavorably against competitor Liquidia Corp in a patent dispute over the rival pulmonary hypertension drug Yutrepia, reducing competitive pressure on UTHR's Tyvaso franchise (web_catalyst via Google AI Overview). Volume reached 1.85M shares, 4.87x the time-adjusted average, signaling strong conviction behind the move. UTHR earnings on 2026-11-04 (consensus EPS $6.46); monitor Liquidia's next steps in the patent dispute and any appeals.
This summary describes the catalyst and move as first detected on Sep 30, 2026, 12:22 PM EDT; the stock has continued trading since, so the current price and percentage move (shown above) may be larger or smaller than the figures here.
What it means for United Therapeutics Corporation investors
For United Therapeutics Corporation investors, the balance of recent signals points to a bullish shift. On the constructive side: Material positive event; Strong 12.6% price move with conviction. Weighing against that: New SEC filing — review for material disclosures; New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $567.75, implying +4.7% upside from $542.22. BestStocks rates the overall signal quality medium (75/100). With earnings roughly 35 days out, the next report is the most likely near-term test of the move.
UTHR price reaction
UTHR last traded at $542.22, up $60.75 (+12.62%) from the previous close of $481.47. The session traded on 3.7× average volume (extreme), so the move carried above-average conviction. Over the past month the stock has ranged between $472.21 and $542.22, and it currently sits about 100% of the way up that band.
Bullish and bearish analyst opinions on United Therapeutics Corporation (UTHR)
▲Latest catalyst·strengthens the bull case
The latest catalyst — a materially positive development — it strengthens the bull case.
The consensus analyst price target on United Therapeutics Corporation (UTHR) is $567.75, 4.7% above the recent $542.22. Over the past 90 days analysts logged 0 upgrades, 4 maintains, and 0 downgrades. Here is how the bullish and bearish cases on UTHR line up.
▲ The bullish case
+Wall Street's consensus price target of $567.75 implies +4.7% upside from $542.22.
+The Street's most bullish target is $735.00 (+35.6%).
+Material positive event.
+Strong 12.6% price move with conviction.
+Volume 3.7x average — institutional conviction.
▼ The bearish case
−The most bearish analyst target is $321.00 (-40.8%).
−United Therapeutics Corporation (UTHR) moved -2.10% from $547.06 to $535.57 on 2026-07-13, reaching a new 30-day low.
Bull vs bear balanceBullish Shift
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Sep 30, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
United Therapeutics Corporation moved -2.08% intraday from $489.42 to $479.26. United Therapeutics (NASDAQ:UTHR ) stock experienced a minor pullback of about 1.6% to 1.9% on September 24, 2026, largely reflecting general market consolidation and normal trading fluctuations rather than a major negative corporate catalyst.🔎 Market Context & Recent Activity - Broad sector pressure: Specialty pharmaceutical and biotech peers also saw minor downward shifts. - Post-announcement settling: The stock has been digesting recent announcements, including an accelerated share repurchase agreement and ongoing competitive landscape discussions regarding its pipeline treatments like Tyvaso and Ralinepag. If you'd like, I can provide: - An overview of recent earnings performance - Details on the accelerated share repurchase program - Key analyst price targets for the upcoming quarter Let me know how you'd like to proceed.
Material / Earnings2026-09-22+0.9%
UTHR moved -100.00% from its $493.98 open to a $497.59 close on 2026-09-22.
Material / Earnings2026-09-15-0.5%
United Therapeutics Corporation (UTHR) moved -1.01% from $505.44 to $500.35 on 2026-09-15. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. The move occurred on elevated volume (2.7x the 5-day average), suggesting institutional activity rather than a reaction to disclosed company news.
Material / Earnings2026-09-04-0.5%
United Therapeutics Corporation (UTHR) moved +0.68% from $484.33 to $487.61 on 2026-09-04. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. The move occurred on below-average volume and coincided with UTHR reaching a new 30-day low.
United Therapeutics fell 6.49% to $479.45, with recent insider selling by CEO Martine Rothblatt and other executives (transactions reported August 28–September 1) cited as a potential factor alongside competitive pressures in key treatments like Tyvaso from rivals such as Liquidia. Volume of 267,014 shares was 1.35x the 150-minute historical average, indicating normal trading activity for this time of day.
Material / Earnings2026-08-28-2.4%
United Therapeutics Corporation (UTHR) moved -2.84% from $530.50 to $515.46 on 2026-08-28. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was near its 5-day average, suggesting the move was not driven by unusual trading activity.
Material / Earnings2026-08-27+2.2%
United Therapeutics Corporation (UTHR) moved +2.71% from $514.00 to $527.91 on 2026-08-27. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was near its 5-day average, suggesting the move was not driven by unusual trading activity.
United Therapeutics declined 2.00% to $501.47 following Q2 2026 earnings that missed revenue consensus at $783.3M (down ~2% YoY), despite an EPS beat, combined with competitive pressures on its core Tyvaso franchise and recent insider selling by CEO Martine Rothblatt (~$5M in shares), per web synthesis corroborated by Yahoo Finance and Investing.com. Volume ran 0.52x expected for this stage of the session, below-average participation.
Upcoming catalysts & outlook
Next earnings
2026-11-04 (est.)
in 35 days
Thesis shift
Bullish Shift
bullish signal
Risk level
Low
from change events
Frequently asked questions about UTHR
Why did United Therapeutics Corporation (UTHR) stock move?
UTHR climbed 12.6% to $542.22. The move coincided with the context summarized above, though no single company-specific catalyst was independently confirmed.
How much did UTHR stock rise?
UTHR gained 12.62% ($60.75) versus the prior close of $481.47, last trading at $542.22 on 3.7× average volume.
When is United Therapeutics Corporation's next earnings date?
UTHR's next earnings report is estimated for 2026-11-04 — about 35 days away.
What is the analyst price target for UTHR?
The consensus analyst price target for UTHR is $567.75, about 4.7% above the current $542.22. Over the past 90 days, analysts recorded 0 upgrades, 4 maintains, and 0 downgrades.
How BestStocks tracks UTHR
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared UTHR-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for UTHR, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of September 30, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
